J. Lawson

发表

Protein flexibility and intrinsic disorder

P. Radivojac, S. Vucetic, Z. Obradovic, 2004, Protein science : a publication of the Protein Society.

Intrinsically disordered protein.

Christopher J. Oldfield, K. W. Hipps, C. Brown, 2001, Journal of molecular graphics & modelling.

Intrinsic disorder and protein function.

A Keith Dunker, Zoran Obradović, Lilia M Iakoucheva, 2002, Biochemistry.

Intrinsic disorder in cell-signaling and cancer-associated proteins.

L. Iakoucheva, Z. Obradovic, A. Dunker, 2002, Journal of molecular biology.

Intrinsic Disorder and Protein Function

L. Iakoucheva, Z. Obradovic, A. Dunker, 2002 .

Fragment-based drug discovery of potent and selective MKK3/6 inhibitors.

J. Lawson, M. Hixon, C. Grimshaw, 2016, Bioorganic & medicinal chemistry letters.

Design, synthesis and optimization of novel Alk5 (activin-like kinase 5) inhibitors.

J. Lawson, M. Hixon, D. Dougan, 2016, Bioorganic & medicinal chemistry letters.

Design and Discovery of MRTX0902, a Potent, Selective, Brain-Penetrant, and Orally Bioavailable Inhibitor of the SOS1:KRAS Protein–Protein Interaction

J. Christensen, J. Lawson, Jacob R. Haling, 2022, Journal of medicinal chemistry.

Fragment-Based Discovery of a Small Molecule Inhibitor of Bruton's Tyrosine Kinase.

J. Lawson, D. Dougan, B. Knight, 2015, Journal of medicinal chemistry.

Design, synthesis and optimization of 7-substituted-pyrazolo[4,3-b]pyridine ALK5 (activin receptor-like kinase 5) inhibitors.

J. Lawson, M. Hixon, D. Dougan, 2017, Bioorganic & Medicinal Chemistry Letters.

Fragment-Based Discovery of MRTX1719, a Synthetic Lethal Inhibitor of the PRMT5•MTA Complex for the Treatment of MTAP-Deleted Cancers.

J. Christensen, J. Lawson, P. Olson, 2022, Journal of medicinal chemistry.

Structural Model of the Regulatory Domain of Smooth Muscle Heavy Meromyosin*

J. Lawson, W. Siems, C. Cremo, 2003, The Journal of Biological Chemistry.

DisProt: a database of protein disorder

Zoran Obradovic, Slobodan Vucetic, Vladimir Vacic, 2005, Bioinform..

Discovery of the Bruton's Tyrosine Kinase Inhibitor Clinical Candidate TAK-020 (S)-5-(1-((1-Acryloylpyrrolidin-3-yl)oxy)isoquinolin-3-yl)-2,4-dihydro-3H-1,2,4-triazol-3-one, by Fragment-Based Drug Design.

J. Lawson, D. Balakrishna, D. Dougan, 2021, Journal of medicinal chemistry.

Molecular dynamics analysis of structural factors influencing back door pi release in myosin.

I. Rayment, J. Lawson, E. Pate, 2004, Biophysical journal.

Abstract LB002: Mechanisms of acquired resistance to KRAS G12C inhibition in cancer

P. Jänne, D. Root, R. Heist, 2021, Experimental and Molecular Therapeutics.

Identification of MRTX1133, a Noncovalent, Potent, and Selective KRASG12D Inhibitor.

J. Blake, J. Christensen, J. Lawson, 2021, Journal of medicinal chemistry.

Acquired Resistance to KRASG12C Inhibition in Cancer.

P. Jänne, D. Root, R. Heist, 2021, The New England journal of medicine.

Discovery of Potent, Selective, and Brain-Penetrant 1 H-Pyrazol-5-yl-1 H-pyrrolo[2,3- b]pyridines as Anaplastic Lymphoma Kinase (ALK) Inhibitors.

Tomoaki Hasui, M. Fushimi, K. Saikatendu, 2019, Journal of medicinal chemistry.

IBA Delivery Technique and Media Salts Affected In Vitro Rooting and Acclimatization of Eight Prunus Genotypes

J. Lawson, W. Bridges, J. Adelberg, 2023, Plants.

Residence time and kinetic efficiency analysis of extracellular signal-regulated kinase 2 inhibitors.

J. Lawson, C. Grimshaw, J. Ermolieff, 2015, Analytical biochemistry.

Isolation of chloroform-resistant mutants of filamentous phage: localization in models of phage structure.

A. Dunker, J. Lawson, J. Oh, 1999, Journal of molecular biology.

Selected Approaches to Disrupting Protein–Protein Interactions within the MAPK/RAS Pathway

J. Lawson, John M. Ketcham, Christopher R. Smith, 2023, International journal of molecular sciences.

MET Tyrosine Kinase Inhibition Enhances the Antitumor Efficacy of an HGF Antibody

J. Lawson, P. Vincent, K. Okada, 2017, Molecular Cancer Therapeutics.

Discovery of potent, reversible MetAP2 inhibitors via fragment based drug discovery and structure based drug design-Part 1.

J. Lawson, Christopher Mcbride, P. Farrell, 2016, Bioorganic & medicinal chemistry letters.

Fragment optimization and elaboration strategies – the discovery of two lead series of PRMT5/MTA inhibitors from five fragment hits

J. Christensen, J. Lawson, Misbha Ud Din Ahmad, 2022, RSC medicinal chemistry.

A Back-to-Front Fragment-Based Drug Design Search Strategy Targeting the DFG-Out Pocket of Protein Tyrosine Kinases.

H. Oki, J. Lawson, Terufumi Takagi, 2012, ACS medicinal chemistry letters.

Structure-based optimization of 1H-imidazole-2-carboxamides as Axl kinase inhibitors utilizing a Mer mutant surrogate.

J. Lawson, Walter Keung, J. Kahana, 2017, Bioorganic & medicinal chemistry letters.

Discovery of potent, reversible MetAP2 inhibitors via fragment based drug discovery and structure based drug design-Part 2.

J. Lawson, Christopher Mcbride, P. Farrell, 2016, Bioorganic & medicinal chemistry letters.

Identification of AHCY inhibitors using novel high-throughput mass spectrometry.

J. Lawson, T. Kawamoto, H. Kimura, 2017, Biochemical and biophysical research communications.